Tumor Suppressor MicroRNAs in Clinical and Preclinical Trials for Neurological Disorders

Autor: Austin Lui, Timothy Do, Omar Alzayat, Nina Yu, Su Phyu, Hillary Joy Santuya, Benjamin Liang, Vidur Kailash, Dewey Liu, Sabra S. Inslicht, Kiarash Shahlaie, DaZhi Liu
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Pharmaceuticals, Vol 17, Iss 4, p 426 (2024)
Druh dokumentu: article
ISSN: 17040426
1424-8247
DOI: 10.3390/ph17040426
Popis: Cancers and neurological disorders are two major types of diseases in humans. We developed the concept called the “Aberrant Cell Cycle Disease (ACCD)” due to the accumulating evidence that shows that two different diseases share the common mechanism of aberrant cell cycle re-entry. The aberrant cell cycle re-entry is manifested as kinase/oncoprotein activation and tumor suppressor (TS) inactivation, which are associated with both tumor growth in cancers and neuronal death in neurological disorders. Therefore, some cancer therapies (e.g., kinase/oncogene inhibition and TS elevation) can be leveraged for neurological treatments. MicroRNA (miR/miRNA) provides a new style of drug-target binding. For example, a single tumor suppressor miRNA (TS-miR/miRNA) can bind to and decrease tens of target kinases/oncogenes, producing much more robust efficacy to block cell cycle re-entry than inhibiting a single kinase/oncogene. In this review, we summarize the miRNAs that are altered in both cancers and neurological disorders, with an emphasis on miRNA drugs that have entered into clinical trials for neurological treatment.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje